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 ABSTRACT  
Metformin is unanimously considered as the first-line glucose-lowering agent. Theoretically, 
however, it cannot be prescribed in a large proportion of patients with type 2 diabetes because 
of the presence of numerous contraindications corresponding to situations that may increase 
the risk of lactic acidosis. Various observational data from real life showed that many diabetic 
patients considered as “at risk” still receive metformin, often without appropriate dose 
adjustment, apparently without any harm, especially no increased risk of lactic acidosis. More 
interestingly, recent data suggest that type 2 diabetes patients who are considered as being “at 
risk” because of the presence of traditional contraindications still take benefit from metformin 
therapy, with a reduction of morbidity and mortality compared with other glucose-lowering 
agents, more particularly sulfonylureas. The present review analyzes the benefit-risk balance 
of metformin therapy in special populations, namely patients with stable coronary artery 
disease, acute coronary syndrome or myocardial infarction, congestive heart failure, renal 
impairment or chronic kidney disease, hepatic dysfunction and chronic respiratory 
insufficiency, all conditions that may theoretically increase the risk of lactic acidosis. A 
special attention will be devoted to elderly patients with type 2 diabetes. Indeed, this 
population is growing rapidly and older patients may cumulate several comorbidities 
classically considered as contraindications to the use of metformin. The recent scientific 
literature suggests that reconsidering the contraindications of metformin is urgently needed in 
order to avoid physicians prescribe the most popular glucose-lowering therapy in daily 
clinical practice outside the official recommendations. 
Key-words : Coronary artery disease – Elderly – Heart failure – Lactic acidosis –  Metformin 
– Renal insufficiency – Type 2 diabetes 
 
La metformine révisitée : une revue critique de la balance bénéfice/risque 
chez les patients diabétiques de type 2 dits « à risque »  
RESUME  
La metformine est unanimement considérée comme le premier choix médicamenteux dans le 
traitement du diabète de type 2. Cependant, théoriquement, elle ne peut être prescrite dans une 
large proportion de patients avec un diabète de type 2 à cause de l’existence de nombreuses 
contre-indications correspondant aux situations susceptibles d’accroître le risque d’acidose 
lactique. Diverses données observationnelles issues de la vie réelle ont montré que bon 
nombre de patients diabétiques dits à risque reçoivent de la metformine, le plus souvent sans 
ajustement posologique approprié, et apparemment sans dommage, en particulier sans risque 
accru d’acidose lactique. De façon encore plus intéressante, des observations récentes 
suggèrent que les patients avec un diabète de type 2, considérés comme étant “à risque” à 
cause de la présence de contre-indications traditionnelles, tirent tout de même un bénéfice 
d’un traitement par metformine, avec mise en évidence d’une réduction de la morbidité et de 
la mortalité en comparaison avec d’autres agents anti-hyperglycémiants, plus particulièrement 
les sulfamides.  La présente revue analyse la balance bénéfice-risque d’un traitement par 
metformine dans des populations spéciales, à savoir les patients avec une insuffisance 
coronarienne stable, un syndrome coronarien aigu ou un infarctus du myocarde,  une 
insuffisance cardiaque, une insuffisance rénale chronique, une dysfonction hépatique et une 
insuffisance respiratoire chronique, toutes conditions qui théoriquement peuvent augmenter le 
risque d’acidose lactique. Une attention spéciale sera accordée aux patients âgés avec un 
diabète de type 2. En effet, cette population est en augmentation rapide et les patients âgés 
peuvent cumuler plusieurs comorbidités classiquement considérées comme des contre-
indications à l’utilisation de la metformine. Au vu de l’analyse de la littérature récente, il est 
urgent de reconsidérer les contre-indications de la metformine pour éviter que les médecins, 
dans leur pratique clinique au quotidien, continuent à prescrire la thérapie anti-
hyperglycémiante la plus populaire en dehors des recommandations officielles. 
 
Mots-clé : Acidose lactique – Diabète de type 2 – Metformine – Insuffisance cardiaque  – 
Insuffisance rénale – Insuffisance hépatique – Insuffisance coronaire –  Patient âgé  
  
 Introduction  
 Type 2 diabetes (T2DM) is currently considered as the first line pharmacological therapy 
in T2DM [1, 2], a recommendation that has been confirmed in the recent ADA (American 
Diabetes Association)-EASD (European Association for the Study of Diabetes) position 
statement [3]. The main reason is that the glucose-lowering activity of metformin  as 
monotherapy is equal or even better than that of any other oral agent, without inducing 
hypoglycaemia or weight gain. Furthermore, metformin may be successfully combined with all 
other glucose-lowering agents, including insulin [2, 3]. Metformin acts as a cellular AMP- 
activated protein kinase (AMPK) activator, a well-known cellular metabolic sensor [4]. Recent 
data also suggested that it also suppresses hepatic glucagon signalling by decreasing 
production of cyclic AMP [5]. The antihyperglycaemic properties of metformin are mainly 
attributed to suppressed hepatic glucose production, especially hepatic gluconeogenesis, and 
slightly increased peripheral tissue insulin sensitivity [6]. Although the precise biochemical 
mechanism of hypoglycaemic action of metformin remains unclear, it probably interrupts 
mitochondrial oxidative processes in the liver [4] and corrects abnormalities of intracellular 
calcium metabolism in insulin-sensitive tissues (liver, skeletal muscle, and adipocytes) and 
also in cardiovascular tissue [7]. Adverse effects comprise gastrointestinal intolerance and, 
more exceptionally, lactic acidosis [8, 9]. 
 In the United Kingdom Prospective Diabetes Study (UKPDS), among patients allocated 
intensive blood-glucose control, metformin showed a greater effect than sulfonylureas or 
insulin for any diabetes-related endpoint, all-cause mortality, and stroke [10]. A significant 
reduction was also observed regarding myocardial infarction (MI) at the end of the trial in the 
metformin group compared with the conventional group (relative risk or RR=0,61; 95% 
confidence interval or CI ; P< 0,010), which persisted after a post-study follow-up of 10 years 
(RR=0.67 ; 0.51–0.89) [11]. Soon after the publication of the UKPDS, a risk-benefit 
assessment of metformin in T2DM was considered as “very favourable” provided that 
contraindications were respected [12].  
 Nevertheless, although metformin is considered the gold standard since the publication 
of this landmark study, its benefit/risk ratio remains uncertain, including its cardiovascular 
efficacy according to a recent meta-analysis [13]. In addition, the UKPDS recruited 
individuals with newly diagnosed T2DM, and patients with cardiac or renal disease were 
excluded, as in most other clinical trials. Therefore, the risk-benefit ratio may be more 
questionable in a routine population with kidney and cardiovascular (CV) disease because of a 
higher risk of lactic acidosis [14]. 
 Lactic acidosis associated with metformin treatment is a rare but important adverse 
event that may be fatal. Several conditions have been depicted, which may increase the risk of 
lactic acidosis associated with metformin [8]. Schematically, they may be divided into 
circumstances that can (1) promote the formation of lactate by the peripheral tissues because 
of hypoxia (circulatory failure, severe respiratory insufficiency); (2) impair lactate 
metabolism through the pathway of gluconeogenesis (primary or secondary hepatic failure); 
and (3) dramatically increase the levels of metformin ((renal impairment leading to metformin 
accumulation, thereby blocking liver gluconeogenesis) (Figure 1). In a recent Cochrane 
review, there was no evidence from 347 prospective comparative trials or observational cohort 
studies that metformin is associated with an increased risk of lactic acidosis, or with increased 
levels of lactate, compared to other anti-hyperglycaemic treatments [15]. However, all clinical 
trials excluded at risk patients and it is also plausible that published observational studies mainly 
included T2DM patients without well-known contraindications. The scene might be rather 
different in real life. Indeed, a population-based study shows that almost a quarter of patients 
prescribed metformin have contraindications to its use. Furthermore, development of 
contraindications rarely results in discontinuation of metformin therapy [16]. These data have 
been confirmed in several other studies in various countries [17, 18]. Despite this, lactic 
acidosis remains rare[8], even if case reports still continue to be published regularly [9, 19].  
 In the study sample of 19,691 T2DM patients with established atherothrombosis 
participating in the Reduction of Atherothrombosis for Continued Health (REACH) Registry, 
the 2-year mortality rate was significantly lower in patients treated with metformin than in 
those without metformin (adjusted hazard ratio or HR=0.76 ; 0.65-0.89). Of major interest 
regarding the topic of the present review, the metformin-related association with lower 
mortality was consistent among subgroups, noticeably in patients older than 65 years, patients 
with a history of congestive heart failure (CHF), and patients with moderate renal impairment 
(RI) (estimated creatinine clearance or glomerular filtration rate - eGFR - between 30 and 60 
mL/min/1.73 m²) [20].  
 The present review provides an updated evaluation of the use of metformin in patients 
who are considered as at risk of lactic acidosis and for whom the use of metformin is 
contraindicated according to the official label. We will more particularly focus our attention 
on the following special populations: 1) patients with stable coronary artery disease (CAD); 2) 
patients with acute coronary syndrome or MI; 3) patients with CHF; 4) patients with RI or 
chronic kidney disease (CKD); 5) patients with hepatic dysfunction; 6) patients with chronic 
respiratory insufficiency; and  finally 7) elderly patients, who may cumulate several 
comorbidities (Table 1).  
Methods  
 To identify relevant studies, an extensive literature search of MEDLINE was 
performed from January 1990 to February 2013, with the term “metformin” combined with 
“lactic acidosis” , on the one hand, or “metformin” combined with “coronary artery disease”, 
“acute coronary syndrome”, “myocardial infarction”, “congestive heart failure”,  ‘renal 
insufficiency”, “chronic kidney disease”, “hepatic failure”, “respiratory insufficiency” or 
elderly”, on the other hand. No language restrictions were imposed. Reference lists of original 
studies, narrative reviews and previous systematic reviews were also carefully examined.  
  
Results 
1. Metformin in patients with stable coronary artery disease  
According to the ADA-EASD position statement, metformin may have some CV benefits 
and would appear to be a useful drug in the setting of CAD, barring prevalent 
contraindications [3]. 
However, in a first study performed in Israel on 2,395 T2DM patients with CAD, those 
using metformin, alone or in combination with sulfonylureas, exhibited a significantly 
increased mortality compared with T2DM patients without oral glucose-lowering agents 
(Table 1). The conclusion was that until the results of problem-oriented prospective studies 
on oral control of T2DM will be available, alternative therapeutic approaches should be 
investigated in these patients [21]. However, these unfavourable results were not confirmed 
in further studies performed in various countries. 
In a Danish nation-wide study, monotherapy with the most used insulin secretagogues 
seems to be associated with increased mortality and CV risk compared with metformin 
among 9,607 T2DM patients with previous MI. By multivariable Cox proportional-hazard 
analyses including propensity analyses and compared with metformin monotherapy, the 
corresponding HR of all-cause mortality were as follows for various sulfonylureas: 
glimepiride (the most prevalent sulfonylurea in this cohort): 1.30 (1.11-1.44), glibenclamide: 
1.47 (1.22-1.76), and glipizide: 1.53 (1.23-1.89). Results for gliclazide and repaglinide were 
not statistically different from metformin[22]. In another similar study in the US, in 2,721 
T2DM patients with documented CAD, a statistically significant increase in overall mortality 
risk was found with glipizide (HR=1.41; 1.07-1.87) and glyburide (glibenclamide) (HR=1.38; 
1.04-1.83) versus metformin [23].  
The long-term effects of glipizide and metformin on the major CV events were compared 
in 304 T2DM patients who had a history of CAD. Treatment with metformin substantially 
reduced major CV events (composite of recurrent CV events, including death from a CV 
cause, death from any cause, nonfatal MI, nonfatal stroke, or arterial revascularization) in a 
median follow-up of 5.0 years compared with glipizide (HR=0.54 ; 0.30-0.90). No difference 
was observed between the two groups regarding all-cause mortality, but the study had no 
sufficient statistical power to detect specifically such a difference[24]. 
Optimal treatment for patients with both T2DM and stable ischemic heart disease has 
been investigated in the large prospective randomized trial BARI-2D with 2,368  T2DM 
patients. At 5 years, there was no significant difference in the rates of death and major 
CVevents between patients undergoing prompt revascularization and those undergoing 
medical therapy or between strategies of insulin sensitization (metformin and/or 
thiazolidinedione) and insulin provision (insulin and/or sulfonylurea). Unfortunately, the 
results cannot distinguish between the effect of either insulin-sensitizer agent (metformin or 
thiazolidinedione) and thus it is impossible to analyze specifically the effect of metformin per 
se [25]. In a retrospective analysis of the Prevention of Restenosis with Tranilast and its 
Outcomes Trial, use of  sensitizer therapy (here metformin with or without additional 
therapy) in T2DM patients undergoing coronary interventions appeared to decrease adverse 
clinical events, especially death (odds ratio or OR=0.39 ; 0.19-0.77) and MI (OR=0.31 ; 0.15-
0.66), compared with diabetic patients treated with nonsensitizer therapy (insulin and/or 
sulfonylureas) [26]. 
BOX : In patients with stable CAD, metformin is associated with a better CV prognosis 
than sulfonylureas. Stable CAD should not be considered as a contraindication to the use of 
metformin in patients with T2DM. 
 
2. Metformin in patients following acute coronary syndrome  
In a retrospective study evaluating the associations of T2DM and glucose-lowering 
strategies with clinical outcomes after acute coronary syndrome, hypoglycaemic therapy 
including only insulin and/or sulfonylurea (insulin-providing; n = 1,473) was associated with 
higher 90-day death/MI/severe recurrent ischaemia compared with therapy that included only 
biguanide and/or thiazolidinedione therapy (insulin-sensitizing; n = 100) (adjusted OR or 
OR=2.1 ; 1.2-3.7). Again, the study protocol did not allow analyze specifically the effect of 
metformin [27]. In another retrospective cohort study of 24,953 Medicare beneficiaries with 
diabetes discharged after hospitalization with acute MI, after multivariable analysis there was 
only a trend for lower 1-year mortality rates in patients treated with  metformin (HR=0.92 ; 
0.81-1.06) compared with patients prescribed an antihyperglycaemic regimen that included 
no insulin sensitizer [28].  
In a nationwide population-based follow-up study among all Danish patients hospitalised 
with first-time MI from 1996 to 2004, the overall cumulative 30 day and 1 year mortality 
rates were lower in patients treated with metformin compared with patients receiving 
sulfonylureas, but the differences vanished after multiple adjustments (Table 2) [29]. 
In patients with T2DM admitted with acute MI not treated with emergent percutaneous 
coronary intervention, monotherapy treatment with sulfonylureas was associated with 
increased CV mortality (HR=1.28; 1.14-1.44), composite of CV death and non-fatal MI 
(HR=1.20; 1.08-1.33) and all-cause mortality (HR=1.25; 1.13-1.40) compared 
with metformin monotherapy [30]. Later on, the same group confirmed a 2 to 3 increased risk 
of CV mortality, CV mortality and nonfatal MI and all-cause mortality, respectively, with 
glyburide (glibenclamide) compared to metformin [31]. 
In a post hoc analysis of the total Diabetes Mellitus Insulin-Glucose Infusion in Acute 
Myocardial Infarction (DIGAMI) 2 cohort as an epidemiological database, mortality and 
morbidity rates were assessed by glucose-lowering treatment during an extended period of 
follow-up (median 4.1 and max 8.1 years) in 1,145 patients with MI and T2DM. In contrast 
to sulfonylureas and insulin, metformin was associated with a lower mortality rate (HR=0.65; 
0.47-0.90), a lower risk of death from malignancies (HR=0.25 ; 0.08-0.83) and a trend for a 
lower risk of CV deaths (HR 0.72 ; 0.49-1.06). In that study, metformin seems to be 
protective against risk of death, while insulin may be associated with an increased risk of 
non-fatal cardiac events [32]. 
In another dedicated study, chronic pretreatment with metformin has been shown to be 
associated with the reduction of the no-reflow phenomenon in 154 patients with T2DM after 
primary angioplasty for a first ST-segment elevation MI (4.2 and 14.6%, P < 0.05 ) [33]. 
The finding that metformin limits MI size and remodeling in animal models 
of MI suggests that patients suffering from myocardial ischaemia could benefit from 
treatment with metformin, even when these patients do not have diabetes [34].  Currently, 
several clinical trials are being performed to test this hypothesis. As an example, the 
Glycometabolic Intervention as adjunct to Primary percutaneous intervention in ST elevation 
myocardial infarction (GIPS)-III trial is a prospective, single center, double blind, 
randomized, placebo-controlled trial, which is currently studying the efficacy of metformin 
with the aim to preserve left ventricular ejection fraction in non-diabetic patients presenting 
with ST elevation MI (STEMI) [35]. 
BOX : In patients with acute coronary syndrome (MI or revascularization), metformin  is 
associated with a better short-term and long-term prognosis than other glucose-lowering 
agents. Acute coronary syndrome should not be considered as a contraindication to the use 
of metformin in patients with T2DM, provided that there is no circulatory failure. 
 
3. Metformin in patients with congestive heart failure 
The use of metformin is common and has increased rapidly in Medicare beneficiaries 
with diabetes and CHF in direct contrast with explicit warnings against this practice by the 
Food and Drug Administration [36]. However, whereas, traditionally, CHF was considered a 
contraindication to the use of metformin, more recent evidence has shown that this should no 
longer be the case [37, 38]. 
In a retrospective cohort study of 16,417 Medicare beneficiaries with T2DM discharged 
after hospitalization with the principal discharge diagnosis of CHF, crude 1-year mortality 
rates were lower among the 1,861 treated with metformin (24.7%) compared with that among 
the 12,069 treated with no insulin-sensitizing drug (metformin or thiazolidinedione : 36.0%, P 
<0.0001). In multivariable models, treatment with metformin was associated with 
significantly lower risks of death (HR=0.87 ; 0.78-0.97), while there was no association 
between reduced mortality and treatment with sulfonylureas or insulin. There was a lower risk 
of readmission for CHF with metformin treatment (HR=0.92 ; 0.86-0.99), contrasting with a 
higher risk for thiazolidinedione. This observational study suggested that metformin is not 
associated with increased mortality and may improve outcomes in older patients with diabetes 
and CHF [39]. 
Using the Saskatchewan Health databases in the US, T2DM patients with incident 
CHF (n=1,833) were grouped according to antidiabetic therapy: metformin monotherapy 
(n=208), sulfonylurea monotherapy (n=773), or combination therapy (n=852). After an 
average follow-up 2.5 years and compared with sulfonylurea therapy, fewer deaths occurred 
in subjects receiving metformin: HR=0.70; 0.54-0.91 for monotherapy and HR=0.61; 0.52-
0.72 for combination therapy. A reduction in deaths or hospitalizations was also observed: for 
metformin monotherapy HR=0.83 ; 0.70-0.99 and for combination therapy HR=0.86 ; 0.77-
0.96). Thus, metformin, alone or in combination, in subjects with T2DM and CHF was 
associated with lower morbidity and mortality compared with sulfonylurea monotherapy [40]. 
A nationwide retrospective cohort study investigated the risk of all-cause mortality 
associated with individual glucose-lowering treatment regimens used in current clinical 
practice in Denmark. Again, treatment with metformin was associated with a lower risk of 
mortality in diabetic patients with CHF compared with treatment with a sulfonylurea 
(HR=0.85 ; 0.75-0.98) or with insulin [41]. 
A case-control study nested within the U.K. General Practice Research Database 
cohort showed that the current use of metformin monotherapy (adjusted OR=0.65; 0.48-0.87) 
or metformin with or without other agents (OR=0.72; 0.59-0.90) was associated with lower 
mortality compared with patients who were not exposed to antidiabetic drugs whereas use of 
other oral glucose-lowering agents drugs or insulin was not associated with all-cause 
mortality [42]. 
The association between metformin use and the risk of death or risk of hospitalization 
was examined in a national cohort of 6,185 patients with CHF and diabetes treated in 
ambulatory clinics at Veteran Affairs medical centers. In the propensity score-matched 
analysis (n=2,874) at 2 years of follow-up, death occurred in 16.1% of patients receiving 
metformin compared with 19.8% of patients not receiving metformin (HR=0.76; 0.63-0.92; 
P<0.01). Hospitalization related to CHF or total hospitalization rates were not significantly 
different between individuals treated with metformin compared with those not treated with 
metformin [43]. 
In patients having T2DM with established atherothrombosis participating in the 
REACH Registry, a significant reduction of 2-year death was associated with metformin 
therapy in patients with a history of CHF (HR=0.69 ; 0.54-0.90) [20]. 
Despite uncertainty in the scientific literature because of the observational nature of the 
published data, there does not appear to be clinical uncertainty with regards to the safety or 
effectiveness of metformin in CHF making a definitive randomized trial virtually impossible 
[44]. Metformin, previously contraindicated in CHF, can now be used if the ventricular 
dysfunction is not severe, if patient’s CV status is stable and if renal function is normal [3, 
45]. However, diabetic patients with elevated systolic blood pressure are at increased risk for 
developing acute decompensated CHF, which is often associated with decreased kidney 
function. During acute decompensated CHF, timely treatment may prevent the decrease in 
kidney function to the threshold associated with an increased risk of metformin-associated 
lactic acidosis. Metformin should not be withheld in diabetic patients with stable CHF who do 
not have other risk factors for acute decompensated CHF or lactic acidosis [46]. 
BOX : In patients with stable CHF, consistent observational data showed that metformin  
is associated with a better overall prognosis than other glucose-lowering agents. Stable CHF 




4. Metformin in patients with renal insufficiency 
Metformin undergoes renal excretion [47, 48]. The population mean renal clearance 
(CL(R)) and apparent total clearance after oral administration (CL/F) of metformin were 
estimated to be 510±130 mL/min and 1140±330 mL/min, respectively, in healthy subjects and 
T2DM patients with good renal function. Over a range of renal function, the population mean 
values of CL(R) and CL/F of metformin are 4.3±1.5 and 10.7±3.5 times as great, respectively, 
as the clearance of creatinine. As the CL(R) and CL/F decrease approximately in proportion 
to the clearance of creatinine, the dosage of metformin should be reduced in patients with RI 
in proportion to the reduced eGFR [48]. The prolonged elimination of metformin in patients 
with CKD, inversely correlated with creatinine clearance, explain the risk of metformin 
accumulation in case of RI [49]. 
Classically, CKD (creatinine clearance < 60 mL/min) represents a contraindication to 
the use of metformin in patients with T2DM [12]. In case of RI, metformin may, indeed, 
accumulate, block gluconeogenesis and cause lactic acidosis, a harmful complication that may 
be fatal [9, 50].  Most cases reporting severe lactic acidosis concern patients with quite severe 
RI, although, renal dysfunction may only be a prerequisite for metformin accumulation 
[8].What so ever, because of this contraindication, very few data are available in the literature 
regarding the use of metformin in patients with moderate RI. In contrast to what has been 
reported for other glucose-lowering agents, especially the new incretin-based therapies, no 
specific trials have been performed assessing the benefit-risk balance of metformin use in 
patients with moderate or severe RI [51]. In the various series reporting real-life data, patients 
receiving metformin despite the presence of RI as official contraindication are not rare, 
apparently without any harm [16-18]. In the fourth National Health and Nutrition 
Examination Survey (NHANES IV), the proportion of patients using metformin progressively 
decreases according to the severity of RI, from 45.6 % at stage 1 to 23.8 at stage 3 and 0 % at 
stages 4 and 5 [52]. Retrospective database analysis using GE Centricity Outpatient Electronic 
Medical Records in the US showed that after the eGFR calculation, almost no patients with 
orders for metformin received doses of the drug appropriate for their degree of RI [53]. While 
metformin is frequently used at inappropriate doses in patients with RI, the clinical 
consequences of these findings remain poorly understood.  
According to the results of REACH, metformin was prescribed worldwide in 1,572 
patients with moderate renal failure (KDOQI stage 3) in contraindication to guidelines for its 
use [54]. Among this subgroup, metformin use was associated with at least a similar reduction 
in mortality as among the overall population. The 2-year mortality rate associated with 
metformin versus other glucose-lowering agents was significantly lower in patients with an 
eGFR of 30 to 60 mL/min/1.73 m². The reduction was even greater than that observed in 
patients with an eGFR  ≥ 60 mL/min/1.73 m² (Table 3) [20]. These findings were confirmed 
in a cohort study from the Swedish National Diabetes Register involving 51 675 patients with 
T2DM and different levels of renal function. Metformin, compared with any other treatment, 
showed similar reduced risks of all-cause mortality in patients with eGFR 45-60 ml/min/1.73 
m² and in patients with eGFR > 60 ml/min/1.73 m². No benefit, but not harm, was observed 
with metformin therapy in patients with eGFR 30-45 ml/min/1.73 m² (Table 3) [55]. 
BOX : In patients with mild to moderate CKD, consistent observational data showed that 
metformin  is associated with a better overall prognosis (including all-cause mortality) than 
other glucose-lowering agents and that the risk of lactic acidosis in absence of acute 
intercurrent event is very low. Stable mild to moderate (with appropriate dose reduction) 
CKD should not be considered as an absolute contraindication to the use of metformin in 
patients with T2DM. 
 
5. Metformin in patients with hepatic dysfunction 
Liver plays a major role in gluconeogenesis and hepatic failure may dramatically hamper 
lactate removal through this biochemical pathway (Figure 1). Given the importance of the 
liver in lactate clearance, it has been suggested focusing on the severity of and prognosis for 
liver disease. Indeed, in many cases, as already mentioned, renal dysfunction is only a 
prerequisite for metformin accumulation, which may only be dangerous per se when 
associated with liver failure [8].Therefore hepatic failure, such as in advanced cirrhosis or 
severe liver hypoperfusion, is considered as a contraindication for using metformin in 
patients with T2DM. Nevertheless, no specific studies have been performed with metformin 
in patients with liver failure.  
However, a recent observational prospective cohort of 100 consecutive diabetic patients 
with ongoing HCV cirrhosis and no contraindication for metformin were included in a 
screening program for hepatocellular carcinoma. After a median follow-up of 5.7 years, use 
of metformin was independently associated with reduced incidence of hepatocellular 
carcinoma (HR=0.19; 0.04-0.79) and liver-related death/transplantation (HR=0.22 ; 0.05-
0.99) [56]. Thus, metformin may not be contraindicated in patients with compensated 
hepatitis C cirrhosis but rather may provide benefits [57].  Further studies are needed to 
confirm this observation. 
 Liver dysfunction associated with non-alcoholic fatty liver disease (NAFLD) or even 
non-alcoholic steatohepatitis (NASH) should be distinguished from true hepatic failure. Mild 
to moderate steatosis is a common finding in overweight/obese patients with T2DM. 
Metformin may be prescribed in that population without any harm [58]. Especially no 
increased risk of lactic acidosis has been reported. Metformin may potentially exert beneficial 
effects in patients with NAFLD, although the evidence remains rather scarce [59-61]. 
Contrasting results were reported in young individuals with fatty liver, with a reduction in 
prevalence and severity after 6 months of metformin in one study [62], but no better results 
compared to lifestyle after 24 months of metformin in another study [63]. In participants from 
the Edinburgh Type 2 Diabetes Study, unexpectedly, the use of metformin was associated 
with the presence of hepatic steatosis (compared with those classed as normal/probable 
normal) on ultrasound scan, independently of BMI and glycemic control (OR=2.19 ; 1.59–
3.00) [64]. Because previous studies of the use of metformin in NAFLD have shown a 
positive or neutral effect in individuals [65], it seems unlikely that there is a causative link 
between metformin use and NAFLD in that study. A specific study compared the effects of 
metformin with that of a thiazolidinedione in adult T2DM patients.  Both agents increased 
hepatic insulin sensitivity. However, metformin did not decrease liver fat or increase insulin 
clearance, in contrast to rosiglitazone [66]. In another study, metformin does not provide 
specific beneficial effects in adult patients with NAFLD, in contrast to pioglitazone [67]. 
According to the conclusion of recent practical guidelines for the management of NAFLD 
based on an extensive review of the literature [59], metformin has no significant effect on 
liver histology and is not recommended as a specific treatment for liver disease in adults with 
NASH[68]. 
BOX : In patients with NAFLD, metformin may be used but no substantial improvement 
in liver fat content should be expected (in contrast to what was observed with 
thiazolidinediones). Limited data are available supporting the use of metformin in patients 
with liver failure, which remains a contraindication.  
 
6. Metformin in patients with chronic respiratory insufficiency 
Severe chronic respiratory insufficiency may lead to hypoxia and thereby enhance 
anaerobic glycolysis and promote lactic acid formation (Figure 1). It is the reason why such 
medical condition is a traditional contraindication for the use of metformin. However, there is 
no specific study demonstrating the precise risk of using metformin in such a population with 
chronic respiratory insufficiency, neither the level of severity that represents an absolute 
rather than a relative contraindication for metformin use. Pulmonary diseases and respiratory 
insufficiency are noticed in some reports on inadequate use of metformin [17, 18]. The risk of 
lactic acidosis associated with metformin therapy in T2DM patients with chronic respiratory 
disease is most probably very low, if still existing, in absence of concomitant hepatic failure 
and/or RI. Furthermore, as discussed by Lalau, the relationship between metformin and lactic 
acidosis is complex, since use of the drug may be causal, co-responsible or simply 
coincidental [8].  
Quite surprisingly, but of potential interest, recent experimental data showed that 
metformin reduces both airway inflammation and remodeling at least partially through the 
induction of AMPK activation and decreases oxidative stress. These data provide insight into 
the beneficial role of metformin as a novel therapeutic drug for chronic asthma [69]. 
BOX : No data are available regarding the use of metformin in T2DM patients with 
chronic respiratory disease. Consequently, severe chronic respiratory insufficiency is a 
contraindication to the use of metformin because of the risk of hypoxia and lactic acidosis.  
 
7. Metformin in elderly patients 
Overall, there is a scarcity of data regarding the use of pharmacological agents, in 
general, and glucose-lowering agents, in particular, in older adults with T2DM, and clinical 
guidance is largely based on data obtained from younger populations [70]. According to a 
recent position statement, strategies specifically minimising the risk of low blood glucose may 
be preferred in older people with T2DM, a pharmacodynamic characteristic shared by 
metformin [3].  
In a preliminary limited study of 24 elderly patients with T2DM (aged between 70-88 
years), the conclusion was that provided the dosage is adjusted to renal function, the 
metabolic tolerance of metformin therapy is satisfactory [71]. A more recent study suggested 
that the efficacy of metformin in Japanese elderly patients with T2DM is not different from 
that in non-elderly patients, and that its safety might be linked to specific and well-
documented contraindications rather than age itself [72]. Another recent study performed in 
Poland indicated a relatively good tolerability of metformin by elderly patients (mean age = 
67 years) despite the presence of the traditional contraindications to this drug [73] . 
Finally, and most interesting, in the above mentioned REACH registry, the overall 
lower 2-year mortality rate in T2DM  patients with atherothrombosis treated with metformin 
versus without metformin was confirmed in the large cohort of subjects aged 65-80 years 
(Table 3) [20]. This reduction was only slightly lower than that observed in the younger age 
group. Less T2DM patients above 80 years were included in this registry, with no mortality 
difference between those receiving metformin or not. In this very old group, even if the 
benefit was not significant, no harm could be detected. Similar reassuring findings were found 
in the 1990-2005 UK general practice research database. Compared to sulfonylureas of 
second generation, metformin was associated with a significant reduction in all-cause 
mortality both in patients older than 65 years and in patients 65 years old and younger at 
initial prescription (Table 3) [74].  
BOX : Observational data suggested that the use of metformin is not harmful in elderly 
T2DM patients but rather that metformin may be associated with more favourable outcomes 
(including overall mortality) compared to other glucose-lowering agents, as previously 
observed  in younger T2DM patients. Thus, old age per se should not be considered as a 
contraindication to the use of metformin, in absence of other absolute contraindications. 
However, despite the fact that metformin is widely prescribed in the elderly, no specific trial 
has been devoted to this special population with the aim of assessing the benefit/risk ratio. 
 
8. General discussion 
 Considering all these observational data recently published in the international literature, 
one may better understand the rather provocative title of a paper already published several years 
ago  “Contraindications can damage your health -  is metformin a case in point ?” [75]. We will 
briefly discuss the benefit/risk balance of metformin in T2DM patients with CV disease, in 
patients with RI and in the elderly population. 
 
8.1.Metformin and CV disease 
CV disease still remains the main cause of mortality in patients with T2DM and tackling 
this common complication requires a multifactorial approach [76]. Diabetic patients with RI 
have an even greater risk of suffering and dying from CV disease. Therefore, CV protection 
in patients with T2DM represents a major objective in clinical practice. Although it remains a 
matter of controversy [13], metformin may offer CV protection, both in patients with newly 
diagnosed T2DM [10] and at a later stage of the disease in insulin-treated patients [77]. 
Putative CV beneficial action exerted by metformin on arterial vessels may be explained by 
its effects on lipids, inflammation, haemostasis, endothelial and platelet function and vessel 
wall abnormalities [78]. 
Experimental studies showed that AMPK activators (like metformin) attenuate 
cardiomyocytic apoptosis during cardioplegia-induced hypoxia/reoxygenation injury. Several 
mechanisms have been proposed to explain such cardioprotection by metformin, including 
lessening endoplasmic reticulum stress, inhibition of cellular unfolded protein response, 
eNOS activation and increased expression of PGC-1α, a key controller of energy metabolism 
in muscle, which is down-regulated in diabetic conditions [79-81]. 
Chronic metformin treatment augments myocardial resistance to ischemia-reperfusion injury, 
by alternative mechanisms in addition to the lowering of blood glucose. 
Thus, metformin prescribed chronically to T2DM patients may lead to a basal state of 
cardioprotection, thereby potentially limiting the occurrence of myocardial damage by 
cardiovascular events [81]. 
 
8.2. Metformin and CKD 
The 2012 update of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical 
Practice Guideline for Diabetes and Chronic Kidney Disease (CKD) is intended to assist the 
practitioner caring for patients with diabetes and CKD [82]. 
Recent data suggested that metformin may be administered with caution in patients with 
creatinine clearance 45-60 mL/min or even lower (30-45 mL/min), provided that the daily 
dose is reduced by half and kidney function is regularly monitored [83]. In patients without 
comorbid conditions that would predispose them to lactic acidosis, elevated serum creatinine 
levels (or reduced GFR) should be considered a risk factor for the development of lactic 
acidosis but not an absolute contraindication [84]. In daily clinical practice, development of 
contraindications, including RI, rarely results in discontinuation of metformin therapy and, 
despite this, lactic acidosis remains a rare event [16, 85]. In some studies, the prevalence of 
T2DM receiving metformin despite having a contraindication (including a GFR < 60 
mL/min) was over 80%. Nevertheless, metformin use in such conditions did not appear to 
increase the risks of lactic acidosis, hospitalization and death [86]. Besides the possibility that 
creatinine levels are not appropriately assessed by physicians initially and during follow-up, 
another explanation for the common use of metformin in T2DM with RI may be that 
prescribers judge that benefits of therapy outweigh potential risks [87]. There are more and 
more data suggesting that meformin can be used in stable mild to moderate CKD and that not 
prescribing metformin in these patients may cause more harm (no optimal protection against 
CV disease, for instance) compared to the benefits of avoiding potentially rare complications 
(in this case, lactic acidosis) [75, 88, 89]. These observations led to a recent position 
statement in which metformin may be used down to a GFR of 30 mL/min, with dose 
reduction advised at 45 mL/min (Figure 2) [3, 82]. This would lead to safely prescribing 
metformin in patients with an eGFR < 60 mL/min/1.73 m², and more importantly in medical 
practice, according to the law [90, 91].  
However, the risk of lactic acidosis should not be neglected [9, 89, 92] and the drug 
should be immediately stopped in presence of unstable RI, any acute event (high fever for 
instance), gastrointestinal disorders (diarrhea, vomiting), dehydration, ..., all conditions that 
can rapidly deteriorate renal function [9, 92]. Last but not least, the use of nephrotoxic agents 
(nonsteroidal anti-inflammatory drugs, … ) should also be avoided in any patient with renal 
dysfunction, especially in those of stage 3 CKD on metformin therapy. 
8.3. Metformin and elderly 
The selection of appropriate drug regimens for older T2DM patients remains challenging. The 
substantial risk of hypoglycaemia with insulin secretagogues such as sulfonylureas is well 
recognized in this population. In this regard, metformin may offer a substantial benefit [70]. 
However, no clinical trial was specifically devoted to the risk/benefit balance of metformin in 
elderly patients with T2DM. Paradoxically, the best evidence can be found in clinical trials 
focusing on the effect of gliptins (dipeptidyl peptidase-4 inhibitors) because these new oral 
incretin-based glucose-lowering agents were either compared to metformin or combined with 
metformin as basal therapy [93, 94]. These recent data confirmed that metformin is effective 
and well tolerated in older patients with T2DM, although old diabetic patients included in 
clinical trials may not be fully representative of the elderly population in real life. 
Because elderly patients with T2DM are exposed to multiple comorbidities, physicians 
caring for older adults with diabetes must be able to assess the patient's health status and use 
this information to recommend a treatment plan that is consistent with the patient's personal 
goals for care [95]. In this regard, older T2DM patients who are frail, anorexic, or 
underweight and those with CHF, renal or hepatic insufficiency, or dehydration may not be 
appropriate candidates for metformin therapy [70]. 
In elderly patients with T2DM, beyond the CV risk, another leading cause of death is 
related to cancer. Increasing recent data now support a protective effect of metformin against 
the development of most types of cancer (especially, digestive cancers and breast cancer) and 
its associated mortality [96]. If this concept is confirmed, it would be a pity to deprive T2DM 
patients, only because the problem of old age, from a drug that may be helpful. 
 9. Conclusion 
Metformin represents the cornerstone of glucose-lowering therapy for T2DM. Despite 
its array of benefits that comparatively outweigh alternative oral anti-glycaemic agents, the 
ability of clinicians to prescribe metformin is restricted in many conditions. There are 
numerous contra-indications, reviewed in the present paper, and cautions concerning the 
putative risks of metformin-related side effects that necessitate cessation of metformin. 
Notably the often stated, yet completely unsubstantiated, heightened risk for development of 
lactic acidosis in the context of RI or CHF is particularly contentious. Given its proven 
clinical benefit, restriction of metformin use based on the creatinine cutoffs provided by the 
FDA, or a GFR cutoff of ≤ 60 mL/min/1.73 m², has been called into question. Similarly, 
stable CHF or CAD cannot be considered anymore as a contraindication to the use of 
metformin. Considering the high prevalence of stable RI, CAD and/or CHF in the elderly 
population, the recent published observations regarding the potential benefit/risk balance of 
metformin therapy are of major interest. Nevertheless, more valuable data in the elderly 
population is still required because the evidence is still sparse. Individual benefit/risk ratio 
should be assessed in order not to deprive patients from a potentially beneficial drug but also 
not to expose T2DM individuals to an unacceptable risk. In this regard, the patient-centered 
approach recommended by the ADA-EASD position statement is of major clinical value. 
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Figure 1 : Illustration of the occurrence of lactic acidosis in special circumstances that may 
increase the risk associated to metformin therapy.  
Figure 2 : Proposed recommendations for use of metformin according to renal function 
estimated by glomerular filtration rate( eGFR). (*) Caution : Increase monitoring of renal 




Table 1 : Comparison of benefits and risks associated with metformin use in special 




Risk of lactic acidosis Potential benefits  
Coronary artery 
disease 








Risk of cardiogenic shock 







Hypoxia + functional 
renal insufficiency 
Decreased mortality 




mortality in case of 
moderate renal impairment 
Hepatic failure Reduced gluconeogenesis No data 
Chronic respiratory 
disease 
Hypoxia No data 
Elderly Frailty, comorbidities Possibly decreased 




Table 2 : All-cause-mortality in patients with T2DM and stable coronary artery disease 
(CAD), post-acute coronary syndrome (ACS) or myocardial infarction (MI), or congestive 
heart failure (CHF) receiving metformin therapy compared to oral glucose-lowering therapy 
without metformin (usually sulfonylurea). HR : hazard ratio. 95% CI : 95 % confidence 
interval. 
 Reference Comparator HR 95% CI 





 Schramm et al 
2011 [22] 
Glimepiride 0.77 0.64-0.93 
 Pantalone et al 







Post-ACS or MI Inzucchi et al 
2005 [28] 
Any except insulin-
sensitizing agent  
0.92 0.81-1.06 
 Horsdal et al 2008 
[29] 
Any sulfonylurea 0.58 (***) 0.47-0.72 
 Jorgensen et al 
2010 [30] 
Any sulfonylurea 0.80 0.71-0.88 





 Mellbin et al 2011 
[32] 
Any agent except 
metformin 
0.65 0.47-0.90 





 Eurich et al 2005 
[40] 
Any sulfonylurea 0.70 0.54-0.91 
 Andersson et al 
2010 [41] 
Any sulfonylurea 0.85 0.75-0.98 





 Aguilar et al 2011 
[43] 
Any agent except 
metformin 
0.69 0.54-0.90 
 Roussel et al 2010 
[20] 
Any agent except 
metformin 
0.76 0.63-0.92 
 (*) Compared with sulfonylurea versus no antidiabetic agent : HR=1.11 (0.90-1.36) 
(**) Compared with sulfonylurea versus no antidiabetic agent : HR=0.84 (0.67–1.06)  
(***) 1 year-mortality after multiple adjustments : HR=0.96 (0.71-1.31) 
 
  
Table 3 : All-cause-mortality in patients with T2DM receiving metformin therapy compared 
to any other glucose-lowering agent.  The T2DM population is divided in subgroups 
according to estimated glomerular filtration rate (eGFR), a marker of chronic kidney disease 








vs any other agent 
n 
HR 95% CI 
Roussel et al 
2010 [20] 
>60 4442 vs 6326 0.89 0.71-1.11 
30-60 1572 vs 3388 0.64 0.48-0.86 
Ekström et al 
2012 [55] 
>60 28015 vs 31614 0.87 0.81-0.94 
45-60 4079 vs 6176 0.87 0.77-0.99 





vs any other agent 
n 
HR 95% CI 
Roussel et al 
2010 [20] 
40-65 2987 vs 3859 0.63 0.45-0.89 
65-80 3791 vs 6768 0.77 0.62-0.95 
>80 598 vs 1492 0.92 0.66-1.28 
Tzoulaki et al 
2009 [74] 
<65 NA vs 1114(*) 0.56 0.49-0.625 
>65 NA vs 8492(*) 0.74 0.70-0.78 
 
NA : not available. (*) Compared with sulfonylureas of second generation.  
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